Open Access

Baicalin inhibits influenza virus A replication via activation of type I IFN signaling by reducing miR‑146a

  • Authors:
    • Rui Li
    • Lianxin Wang
  • View Affiliations

  • Published online on: October 15, 2019     https://doi.org/10.3892/mmr.2019.10743
  • Pages: 5041-5049
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Influenza virus A (IVA) is one of the predominant causative agents of the seasonal flu and has become an important cause of morbidity worldwide. Great efforts have been paid to develop vaccines against IVA. However, due to antigenic drift in influenza virus A and rapid emergence of drug‑resistant strains, current available vaccines or anti‑IVA chemotherapeutics are consistently inefficient. Hence, various more broadly effective drugs have become important for the prevention and treatment of IVA. Of these drugs, baicalin, a flavonoid isolated from Radix Scutellaria, is a promising example. However, little is known in regards to its pharmacological mechanism. Here, it was demonstrated that baicalin inhibits the H1N1 and H3N2 viruses in A549 cells. Subsequently, it was found that miR‑146a was markedly downregulated by treatment of baicalin. Additionally, further experiments revealed that miR‑146a was able to promote the replication of H1N1 and H3N2 by targeting TNF receptor‑associated factor 6 (TRAF6), a pivotal adaptor in the interferon (IFN) production signaling pathway, to downregulate type I IFN production, and enrichment of miR‑146a eliminated the anti‑IVA effects of baicalin on the H1N1 and H3N2 viruses. Additionally, in vivo experiments demonstrated that baicalin could protect mice during H1N1 infection. Taken together, our findings firstly illustrated the anti‑IVA molecular mechanism of baicalin and provide new evidence for targeting miRNAs to prevent and treat viral infection, such as the H1N1 and H3N2 viruses.
View Figures
View References

Related Articles

Journal Cover

December-2019
Volume 20 Issue 6

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li R and Li R: Baicalin inhibits influenza virus A replication via activation of type I IFN signaling by reducing miR‑146a. Mol Med Rep 20: 5041-5049, 2019
APA
Li, R., & Li, R. (2019). Baicalin inhibits influenza virus A replication via activation of type I IFN signaling by reducing miR‑146a. Molecular Medicine Reports, 20, 5041-5049. https://doi.org/10.3892/mmr.2019.10743
MLA
Li, R., Wang, L."Baicalin inhibits influenza virus A replication via activation of type I IFN signaling by reducing miR‑146a". Molecular Medicine Reports 20.6 (2019): 5041-5049.
Chicago
Li, R., Wang, L."Baicalin inhibits influenza virus A replication via activation of type I IFN signaling by reducing miR‑146a". Molecular Medicine Reports 20, no. 6 (2019): 5041-5049. https://doi.org/10.3892/mmr.2019.10743